All In Biotech

Drug Trial Radar · NCT07934927

A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma

A Prospective, Single-Arm, Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa Injection and Apatinib Mesylate for Advanced Mucosal Melanoma

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, open-label Phase II clinical study. The main purpose of this study is to evaluate the effectiveness of nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate in patients with advanced mucosal melanoma. Participants will receive treatment with nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate. Each treatment cycle lasts 3 weeks, and participants will receive a total of 6 cycles. Participants whose disease does not progress after the initial treatment will continue maintenance therapy with apatinib mesylate combined with retlirafusp alfa injection until their disease progresses or they experience intolerable side effects. After enrollment, participants will undergo safety visits before each dose on Day 1 and Day 21 of each treatment cycle. Tumor imaging assessments will be performed before treatment and after every 2 to 4 cycles of treatment. Clinical response will be evaluated by radiologists according to the RECIST 1.1 criteria. Researchers will monitor participants for any adverse events throughout the study and will grade the severity of these events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. After treatment is completed, participants will be followed for 12 weeks for safety monitoring, and long-term survival follow-up will continue.

Conditions

  • Melanoma
  • Immune Checkpoint Inhibitor

Interventions

  • Retlirafusp Alfa InjectionDrug

    Drug: Nab-paclitaxel Injection Nab-paclitaxel 200 mg/m² IV infusion Q3W Drug: Retlirafusp Alfa Injection Retlirafusp Alfa diluted in 250 mL normal saline IV, administered 30 minutes before chemotherapy, Q3W Drug: Apatinib Mesylate Tablet Apatinib Mesylate 250 mg PO QD Regimen: Nab-paclitaxel + Retlirafusp Alfa + Apatinib Mesylate, Q3W × 6 cycles (combination phase); maintenance: Apatinib Mesylate + SHR-1701 until disease progression or unacceptable toxicit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR: CR+PR)Time frame: up to 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun yat-sen uniersity

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.